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ABSTRACT
Background: Receptor tyrosine kinases (RTKs) play key roles in tumorigenesis.
The multi-RTK inhibitor dovitinib has demonstrated promising antitumor activity in
multiple cancers.
Patients and Methods: In this phase 2, open-label, single-arm study, patients
with advanced malignancies with RTK-pathway genetic aberrations whose disease
progressed on/following standard treatment received dovitinib (500 mg/day; 5-dayson/2-days-off). The primary endpoint was clinical benefit rate (CBR; complete
response, partial response [PR], or stable disease [SD] for ≥ 16 weeks).
Results: Of 80 patients enrolled, common tumors included gastrointestinal stromal
tumors (GIST; 20.0%), colorectal cancer (CRC; 18.8%), and ovarian cancer (10.0%).
Patients were heavily pretreated (median prior lines = 4; 67.5% had ≥ 3 prior lines).
Genetic aberrations included cKIT (28.8%), FGFR3 (15.0%), and RET (15.0%). The
CBR was 13.8%; one PR (GIST) and 10 SD (adenoid cystic [n = 3]; ovarian [n = 3];
GIST [n = 2]; CRC [n = 1]; gastroesophageal junction [n = 1]). The most common
treatment-related adverse events were fatigue, diarrhea, nausea, and vomiting.
Conclusions: In this heterogeneous patient population, the safety profile was
acceptable for dovitinib therapy. A subset of patients with RTK pathway-activated
tumors experienced clinical benefit. However, the primary endpoint was not met,
suggesting further refinement of predictive biomarkers is required.

INTRODUCTION

Activating mutations in cKIT and PDGFRα are common
in gastrointestinal stromal tumors and are thought to
play crucial roles in tumor initiation [3, 4]. Aberrations
in FGFRs have been observed across multiple tumor
types, most commonly in urothelial, breast, endometrial,
squamous lung cancer, and ovarian cancers [1, 5].
Dovitinib (TKI258) is a small molecule multi-kinase
inhibitor that targets a number of RTKs, including FGFR,
VEGFR, PDGFR, colony stimulating factor 1 receptor
(CSF-1R), cKIT, RET, tropomyosin receptor kinase A
(TrkA), and fms-related tyrosine kinase 3 (FLT3) [6].

Receptor tyrosine kinases (RTKs), including
vascular endothelial growth factor receptor (VEGFR),
fibroblast growth factor receptor (FGFR), platelet-derived
growth factor receptor (PDGFR), and the proto-oncogene
cKIT play multiple roles in tumor growth, development,
and survival [1]. Mutations in RTKs that result in aberrant
signaling have been linked to tumorigenesis [2]. The
prevalence and role of RTK mutations in human cancers
has been the subject of a number of clinical studies.
www.oncotarget.com
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This broad range of targets is the mechanistic basis for
the antiproliferative and antiangiogenic effects of dovitinib
observed in preclinical studies [6–8]. In the clinic,
dovitinib has demonstrated promising activity in a number
of cancers, including as a single agent in gastrointestinal
stromal tumors [9] and in combination with fulvestrant in
advanced breast cancer [10].
In this trial (NCT01831726), dovitinib was
investigated as part of the Novartis Signature Program
(8 phase 2, signal-finding, basket trials of different
single-agent targeted therapies in a genetic alterationspecific manner) [11]. The purpose of this tumor
histology-agnostic study was to determine whether
dovitinib treatment demonstrated sufficient efficacy
in select RTK pathway-activated cancers to support
additional studies.

assessment, 74 patients (92.5%) experienced a treatmentemergent adverse event, suspected to be related to study
drug (Table 2). The most common treatment-emergent–
related adverse events of any grade in ≥ 30% of patients
were fatigue (60.0%) and the gastrointestinal disorders
diarrhea (55.0%), nausea (53.8%), and vomiting (41.3%).
Grade 3/4 treatment-emergent suspected-related adverse
events were experienced by 45 patients (56.3%); fatigue
was the most common in 14 patients (17.5%). Decreased
platelet count, hypertriglyceridemia, and increased gammaglutamyltransferase were the only Grade 4 adverse events
reported in more than 1 patient (2 patients [2.5%] each).
Treatment-emergent adverse events requiring dose
adjustment or interruption, suspected to be related to
study drug, were reported in 45 patients (56.3%); these
were most commonly (in ≥ 5.0% of patients), fatigue
(21.3%), gastrointestinal disorders including nausea
(12.5%), diarrhea (11.3%) and vomiting (7.5%), and
hypertension (5.0%). Adverse events were the cause of
treatment discontinuation in 16 patients (20.0%). Nine
patients (11.3%) died during the study or within 30 days
of treatment discontinuation; of these, death was the
cause of study discontinuation in seven patients (8.8%;
Supplementary Figure 1). Patient deaths were due to
disease progression (n = 5 [6.25%]) and serious adverse
events (n = 4 [5.0%]). The serious adverse events leading
to death were acute thrombotic cerebrovascular event,
pulmonary embolism, acute respiratory failure, and cardiac
arrest. The cases of acute thrombotic cerebrovascular
event and pulmonary embolism were suspected to be
related to study drug.

RESULTS
Patients
Between August 15, 2013 and December 17, 2015,
80 patients with advanced malignancies were enrolled and
received at least one dose of dovitinib. Baseline patient
characteristics are shown in Table 1. The median age was
60 years (range: 29–80) and the patient population was
heavily pretreated with a median number of 4 prior lines
of anticancer therapy (range: 0–14); 67.5% of patients
had received at least 3 prior lines. Gastrointestinal stromal
tumor (20.0%), colorectal cancer (18.8%), and ovarian
cancer (10.0%) were the most common solid malignancies;
no patients with hematologic malignancies were enrolled.
Tumor type cohorts of at least 4 patients were formed
in the following malignancies: gastrointestinal stromal
tumor (n = 16), colorectal cancer (n = 15), ovarian
cancer (n = 8), adenoid cystic carcinoma (n = 7), head
and neck squamous cell carcinoma (n = 5), non-small cell
lung cancer adenocarcinoma (n = 4), and thymus cancer
(n = 4). The most common (in ≥ 15.0% of patients) genetic
aberrations that were required for patient enrollment were
cKIT (28.8%), FGFR3 (15.0%), and RET (15.0%).
At final data cut-off (February 10, 2016) all patients
had discontinued treatment, most commonly due to disease
progression (61.3%; Supplementary Figure 1). The median
duration of dovitinib treatment was 1.78 months (range: 0.1–
16.7) with the majority of patients treated for a maximum
of 2 months (61.3%). The median duration of follow-up
was 29.9 months. Dovitinib dose was reduced in 39 patients
(48.8%) with adverse events the most common reason for
dose reduction in 37 patients (46.3%). The median relative
dose intensity for dovitinib was 100% (range: 40–100).

Efficacy
Clinical benefit was experienced by 11 patients
(13.8%); 10 patients (12.5%) had stable disease for at
least 16 weeks and 1 patient (1.3%) had a partial response
lasting 116 days (Table 3). Stable disease was experienced
by patients in the following tumor cohorts: adenoid cystic
tumor (n = 3), ovarian tumor (n = 3), gastrointestinal
stromal tumor (n = 2), and colorectal tumor (n = 1).
Outside of the tumor cohorts, stable disease was also
reported in an additional patient with a gastroesophageal
junction tumor. The following tumor mutations were
reported in patients with clinical benefit: cKIT (n = 1),
CSF-1R (n = 1), PDGFRα (n = 2), PDGFRβ (n = 1),
VEGFR1 (n = 1), VEGFR2 (n = 2), FLT3 (n = 1), FGFR2
(n = 2), RET (n = 1), and TrkA (n = 1).
The patient with a partial response was a 49-year-old
male with a gastrointestinal stromal tumor and metastatic
sites in the lung, liver, and jejunum. The best percentage
change from baseline in the size of target lesion was –38.6%.
He had received 3 prior lines of therapy. Sequencing
of a stomach tumor biopsy taken 46.1 months prior to
study start per local analysis revealed presence of a cKIT
mutation; posthoc central sequencing analysis highlighted

Safety
Of all patients who received at least one dose
of dovitinib and had at least one post-baseline safety
www.oncotarget.com
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Table 1: Patient baseline characteristics
Characteristic

Patients (N = 80)

Median age, years (range)

60 (29–80)

Sex, n (%)
Female

40 (50.0)

Male

40 (50.0)

Race, n (%)
Caucasian

69 (86.3)

Black

7 (8.8)

Asian

2 (2.5)

Other

2 (2.5)

ECOG PS, n (%)
0

38 (47.5)

1

42 (52.5)

Primary tumor type, n (%)
Gastrointestinal stromal tumor

16 (20.0)

Colorectal cancer

15 (18.8)

Ovarian

8 (10.0)

ACC

7 (8.8)

HNSCC

5 (6.3)

NSCLC adenocarcinoma

4 (5.0)

Thymus

4 (5.0)

Other/unknown

21 (26.3)

a

Prior lines of antineoplastic medication, n (%)
0

4 (5.0)

1

11 (13.8)

2

11 (13.8)

3

13 (16.3)

4

15 (18.8)

≥5

26 (32.5)

Other tumors in fewer than 4 patients were: sarcoma (n = 3), central nervous system, lung non-small cell non-adenocarcinoma, neuroendocrine, pancreas,
and small intestine (n = 2 each), and cervix, gall bladder, gall bladder ducts, gastroesophageal junction, and melanoma (n = 1 each). Primary tumor type was
unknown in 3 patients. Abbreviations: ACC, adenoid cystic carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; HNSCC, head
and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer.
a

an additional mutation in VEGFR2. The patient had received
the following therapies between the date of biopsy and first
dose of dovitinib: imatinib, sunitinib, and regorafenib.
Median progression-free survival in all patients
treated with dovitinib was 2.4 months (95% confidence
interval [CI]: 1.8–3.7) with 60 (75.0%) events. The median
overall survival was 13.5 months (95% CI: 5.9–14.7) with
34 (42.5%) events. Of the 7 tumor cohorts that enrolled at
least 4 patients (adenoid cystic, colorectal, gastrointestinal
stromal, head and neck squamous cell carcinoma, lung nonsmall cell adenocarcinoma, ovarian, and thymus), none
passed the prespecified threshold of benefit according to
Bayesian analysis and futility was declared (Figure 1).

following genes were also common (in ≥ 10% of patients):
FGFR3 and RET (in 15.0% of patients each), and FGFR1
and VEGFR2 (in 10.0% of patients each). The median
time from the date of tumor biopsy used for sequencing to
first dose of dovitinib was 18.8 months (range: <1–120).
The tumor biopsy was obtained within 12 months prior to
dovitinib treatment in 28 patients – genomic alterations are
shown in Figure 2 with specific nucleotide substitutions
detailed in Supplementary Table 2. Of these patients, 13
had received no anticancer therapy from the time of tumor
biopsy to the start of dovitinib therapy. The remaining
15 patients had received at least one line of therapy after
collection of the biopsy sample; 5 of these biopsy samples
were collected at disease onset.
Response rates in those patients with recent biopsies
(within 12 months of study treatment) included 1 patient
who achieved stable disease, 17 patients with progressive
disease, and 10 patients who were not evaluable for

Genomic profiling
The most common protocol-defined genetic
aberration was in cKIT (28.8%; Table 4). Alterations in the
www.oncotarget.com
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Table 2: Treatment-emergent adverse events suspected to be related to dovitinib in ≥ 10% of
patients
Adverse event, n (%)
Any adverse event
Fatigue
Diarrhea
Nausea
Vomiting
Hypertriglyceridemia
Decreased appetite
Increased blood AP
Increased AST
Asthenia
Dehydration
Decreased weight
Increased ALT
Increased GGT
Hypertension
Rash
Thrombocytopenia
Dysgeusia
Increased amylase
Increased lipase

Grade 1
5 (6.3)
12 (15.0)
24 (30.0)
22 (27.5)
21 (26.3)
8 (10.0)
11 (13.8)
5 (6.3)
11 (13.8)
4 (5.0)
2 (2.5)
6 (7.5)
9 (11.3)
3 (3.8)
4 (5.0)
7 (8.8)
5 (6.3)
6 (7.5)
5 (6.3)
5 (6.3)

Patients (N = 80)
Grade 2
Grade 3/4
24 (30.0)
45 (56.3)
22 (27.5)
14 (17.5)
14 (17.5)
6 (7.5)
16 (20.0)
5 (6.3)
8 (10.0)
4 (5.0)
9 (11.3)
6 (7.5)
9 (11.3)
2 (2.5)
8 (10.0)
5 (6.3)
3 (3.8)
1 (1.3)
6 (7.5)
3 (3.8)
9 (11.3)
2 (2.5)
6 (7.5)
0
3 (3.8)
0
4 (5.0)
5 (6.3)
2 (2.5)
4 (5.0)
3 (3.8)
0
0
4 (5.0)
2 (2.5)
0
2 (2.5)
1 (1.3)
0
3 (3.8)

Any grade
74 (92.5)
48 (60.0)
44 (55.0)
43 (53.8)
33 (41.3)
23 (28.8)
22 (27.5)
18 (22.5)
15 (18.8)
13 (16.3)
13 (16.3)
12 (15.0)
12 (15.0)
12 (15.0)
10 (12.5)
10 (12.5)
9 (11.3)
8 (10.0)
8 (10.0)
8 (10.0)

Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; GGT, gammaglutamyltransferase.
clinical benefit. The patient with stable disease and
ovarian cancer was a 52-year-old female who had
previously been treated with 6 lines of therapy including
carboplatin, paclitaxel, cisplatin, carboplatin plus
gemcitabine, insulin-like growth factor binding protein
2-targeted therapy, cyclophosphamide, and letrozole.
The best percentage change from baseline was –5.1%.
Local sequencing analysis of a biopsy from the primary
ovarian tumor collected 2.5 months prior to the study
start, approximately 3 weeks before cessation of letrozole
therapy, revealed the presence of RET and TrkA (NTRK1)
protocol-defined mutations. The following aberrations in
genes known to be implicated in tumor development were
also present: CCNE1, MDM2, MITF, NFKBIA, PIK3CA
amplifications, and short-variant mutations of BCORL1,
CDK12, and TP53.

rate of 13.8% including 1 patient who experienced a partial
response. Clinical benefit was assessed and compared to
historical rates in tumor cohorts of gastrointestinal stromal
tumor, colorectal cancer, ovarian cancer, adenoid cystic
carcinoma, head and neck squamous cell carcinoma,
non-small cell lung cancer adenocarcinoma, and thymus
cancer. Although no tumor histology cohort met the
prespecified threshold associated with success, it should
be noted that the partial response was observed in the
presence of cKIT and VEGFR2 mutations. Several patients
experienced clinical benefit with tumor mutations in cKIT,
CSF-1R, PDGFRα, PDGFRβ, VEGFR1, VEGFR2, FLT3,
FGFR2, RET, and TrkA.
Overall, the observed safety profile in this
heterogenous patient population was acceptable for dovitinib
treatment; the reported adverse events are consistent with
the known safety profile of dovitinib monotherapy [17, 18].
No new safety signals emerged during this study. Adverse
events thought to be related to dovitinib therapy were
experienced by 92.5% of patients, the majority were Grade
2 or 3 in severity. Fatigue and gastrointestinal disorders
including diarrhea, nausea, vomiting, and decreased appetite
were among the most commonly reported adverse events.

DISCUSSION
This signal-seeking study assessed the efficacy of
dovitinib in patients with solid tumors possessing genetic
aberrations in RTKs. The primary endpoint of the clinical
benefit rate was not met, with an observed clinical benefit
www.oncotarget.com
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Table 3: Summary of clinical benefit
Patients (N = 80)
Tumor response, n (%)
Complete response
Partial response
Stable disease (≥ 16 weeks)
Progressive disease
Non-evaluable
Clinical benefit rate, n (%) [95% CI]a
Overall response rate, n (%) [95% CI]b

0
1 (1.3)
10 (12.5)
47 (58.8)
22 (27.5)
11 (13.8) [7.1–23.3]
1 (1.3) [0.0–6.8]

Clinical benefit rate = complete response + partial response + stable disease for at least 16 weeks.
Overall response rate = complete response + partial response. Abbreviation: CI, confidence interval.

a

b

With advances in genomic technologies and a
growing knowledge of actionable mutations in targeted
therapies, the promise of personalized medicine is growing
[19]. In this study, an association between tumor genomic
alteration and response was precluded by the small sample
sizes for each genomic alteration. Additionally, genetic
alterations in other signaling pathways may impact
dovitinib activity. Patient-derived xenograft models have
demonstrated the association between FGF3 and FGF19

upregulation and response to dovitinib [20]. The presence
of additional mutations in related signaling pathways may
not be reflected in the dataset in this study due to the length
of time between tumor biopsy and dovitinib treatment.
There were few patients in which tumor biopsies were
collected within 12 months of study start and only 13
patients who had received no other therapy between tumor
biopsy and dovitinib treatment. In case of the emergence of
treatment-related genetic alterations or suppression, real-

Figure 1: Clinical benefit per tumor type cohorta. aOnly tumor types with at least 4 patients are included. bPatients for whom

clinical benefit was non-evaluable are included under “no clinical benefit” as follows: ACC n = 1; Colorectal cancer n = 2; Gastrointestinal
stromal tumor n = 3; HNSCC n = 3; NSCLC adenocarcinoma n = 1; ovarian n = 3; thymus n = 3. Abbreviations: ACC, adenoid cystic
carcinoma; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; PR, partial response; SD, stable disease.
www.oncotarget.com
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Table 4: Protocol-defined genetic aberrations based on local molecular profiling
Genetic aberration, n (%)
cKIT
FGFR3
RET
FGFR1
VEGFR2
FGFR2
FLT3
PDGFRα
PDGFRβ
TrkA (NTRK1)
CSF-1R
VEGFR1

Patientsa (N = 80)
23 (28.8)
12 (15.0)
12 (15.0)
8 (10.0)
8 (10.0)
7 (8.8)
7 (8.8)
7 (8.8)
5 (6.3)
5 (6.3)
2 (2.5)
0

Patients may have alterations in more than one gene at baseline; as such, the total may exceed 100%.

a

time/fresh tumor biopsies in future trials would ensure the
identified molecular aberrations accurately represent the
tumor genomic background at study start.
Overall, dovitinib therapy was well tolerated in this
heavily pretreated patient population and clinical benefit
was observed in a subset of patients following dovitinib
treatment. Future studies may provide additional insights
into the role of the tumor genomic background in response
to dovitinib therapy.

assessment. Clinical benefit was defined as the proportion of
patients who achieved complete response, partial response,
or stable disease for at least 16 weeks. Tumor response
was assessed according to Response Evaluation Criteria In
Solid Tumors (RECIST) v1.1 for patients with solid tumors;
and appropriate hematologic response criteria for patients
with hematologic tumors [12]. The key secondary endpoint
was the overall response rate, defined as the proportion
of patients who achieved complete or partial response.
Additional secondary endpoints included progression-free
survival, overall survival, duration of response, and safety
and tolerability. The association between pathway activation
and response to dovitinib was an exploratory endpoint.

MATERIALS AND METHODS
Study design, treatment, and objectives

Patient population

This was a phase 2, open-label, basket study in
patients with solid or hematologic malignancies with
mutations, translocations, or activations in specified
RTK pathways whose disease had progressed on or
following standard treatment (NCT01831726). Patients
were treated with 500 mg/day dovitinib on a 5-dayson/2-days-off schedule with 28-day treatment cycles
until unacceptable toxicity, disease progression, death, or
treatment discontinuation for any other reason. There were
no breaks between dosing cycles. Dose interruptions or
reductions were permitted for patients unable to tolerate
the starting dose due to drug-related toxicities; a maximum
of 2 dose reductions were permitted to 400 mg and 300
mg, as needed with no dose re-escalation permitted.
Radiological tumor assessments were performed at
baseline, every 8 weeks (± 4 days) for the first 16 weeks
on study, every 16 weeks (± 4 days) thereafter, and at
the end of treatment. Safety was monitored by physical
examinations, laboratory evaluations, and continuous
reporting of adverse events according to the Common
Terminology Criteria for Adverse Events v4.03.
The primary endpoint was the clinical benefit rate
associated with dovitinib treatment per local investigator
www.oncotarget.com

Adult patients (≥ 18 years) with advanced
(surgically unresectable, recurrent, or metastatic) solid or
hematologic malignancies with a pre-identified mutation
and/or translocation in one or more of the following genes:
cKIT, CSF-1R, FGFR1/2/3, FLT3, PDGFRα/β, RET, TrkA
(NTRK1), and/or VEGFR1/2 were enrolled. Patients with
confirmed amplification of FGFR1/2/3, FLT3, and/or
cKIT were also included. Patients were excluded if they
had a primary diagnosis of any of the following tumor
types: urothelial, hepatocellular carcinoma, endometrial
carcinoma, metastatic breast cancer, squamous non-small
cell lung cancer, renal cell carcinoma, FLT3-mutated acute
myeloid leukemia, and multiple myeloma.
Patients had progressive disease or relapse at
screening, and had received at least one prior treatment for
recurrent, metastatic, or locally advanced disease with no
viable standard therapy options expected to result in durable
response. Patients with solid tumors or lymphoma must
have had measurable disease per RECIST v1.1 or Cheson
2007 [13] criteria, respectively. Patients were excluded if
they had received prior treatment with dovitinib or had a
1240
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Figure 2: Genomic profile and tumor response in patients with biopsy taken within 12 months of study start. Specific

nucleotide substitutions of PIK3CA, PIK3R1, KRAS, and TP53 are shown in Supplementary Table 2. aResponse defined as progressive
disease despite decreased size of target lesion due to progression of existing non-target lesions, the appearance of new lesions, or progressive
disease in target lesion at end of treatment. In the patients with sarcoma and HNSCC, progressive disease was given as the reason for
discontinuation without imaging evidence. Abbreviations: ACC, adenoid cystic carcinoma; CNS, central nervous system; HNSCC, head
and neck squamous cell carcinoma; NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PFS, progressionfree survival; SD, stable disease; SI, small intestine.
www.oncotarget.com
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known hypersensitivity to dovitinib. All patients had an
Eastern Cooperative Oncology Group performance status
of 0 or 1 and a life expectancy of at least 16 weeks. Patients
with a history of pulmonary embolism, untreated deep
venous thrombosis within 6 months prior to study start,
impaired cardiac function, or clinically significant cardiac
disease were excluded. Patients were also excluded if they
had brain metastasis or a history of brain metastasis or
leptomeningeal carcinomatosis.

FLT3: fms-related tyrosine kinase 3; PDGFR: plateletderived growth factor receptor; RECIST: Response
Evaluation Criteria In Solid Tumors; RTK: receptor
tyrosine kinase; TrkA: tropomyosin receptor kinase A;
VEGFR: vascular endothelial growth factor receptor.
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